Project description
Protecting against Ebola in Africa
Since the 2014-2016 outbreak in West Africa, Ebola Virus Disease (EVD) has continued to spread across sub-Saharan Africa, exposing gaps in prevention for those at highest risk. While the r-VSV-ZEBOV vaccine (Ervebo) has been deployed in ring vaccination strategies, its effectiveness for high-risk contacts is increasingly debated. Meanwhile, monoclonal antibodies such as Ansuvimab (Ebanga) and REGN-EB3 (Inmazeb) have reduced mortality in treated patients. The EU-funded EBO-PEP project aims to evaluate the post-exposure prophylaxis (PEP) for high-risk contacts through a multi-country, multi-epidemic clinical trial. It also aims to strengthen African research capacity, foster community engagement and define an evidence-based PEP strategy for future outbreaks.
Objective
Ebola Virus Disease (EVD) outbreaks represent significant threats to public health and require effective countermeasures to minimize transmission and reduce mortality.
The r-VSV-ZEBOV vaccine (Ervebo®) demonstrated efficacy in protecting contacts and contacts of contacts and has since been widely used in ring vaccination strategies in the Democratic Republic of Congo (DRC) outbreaks. However, its efficacy for high-risk contact is more and more debated. Furthermore, two monoclonal antibodies (mAbs), Ansuvimab (Ebanga®) and REGN-EB3 (Inmazeb®), have demonstrated their efficacy as treatment in reducing mortality in patients with EVD.
With the availability of these management and prevention tools, the question of their use in Post-Exposure Prophylaxis (PEP), to protect individuals from contracting EVD after a high-risk contact, is more important than ever to effectively control EVD.
The EBO-PEP consortium built on a highly successful collaboration between African and European institutions and NGOs. and allow to maintain a network for knowledge sharing and consortium collaboration to fight against EVD in Africa.
The overall objective of the EBO-PEP project is to increase the portfolio of therapeutics tools against EVD, by evaluating a PEP strategy for high-risk contact. This will be accomplished through a multi-epidemic, multi-countries phase III clinical trial to test the efficacy of mAbs used as PEP during outbreak period. To address this objective, we focus our activities on 3 specific objectives:
- to set up a multi-epidemic, multi-site and multi-countries phase III clinical trial in Africa to test the efficacy of mAbs used as PEP for EVD high-risk contact (EBO-PEP study),
- to strengthen the capacities of clinical researchers and increase the knowledge and engagement of the community on EVD research,
- to define the best PEP strategy for high-risk contact and to advocate for PEP implementation in the countries affected by EVD.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-JU-GH-EDCTP3-2023-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75654 Paris
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.